This Just In...

Discussion in 'Daiichi-Sankyo' started by anonymous, Feb 8, 2017 at 2:59 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    DSI will commence manufacturing of all current and future products in candy bar form. When asked by reporters, US President Ken Keller said "we have to be different and think outside the box. We have to give our patients what they want, and that's more chocolate. It's our moral responsibility."

    Look for the Welchol candy bar to hit markets early next year.
     

  2. anonymous

    anonymous Guest

    They were going to also have candy bars with almonds in them. But GG said that with peanut allergies rampant, that could potentially be a problem at launch.
     
  3. anonymous

    anonymous Guest

    Finally using their brains for once. Huge relief!
     
  4. anonymous

    anonymous Guest

    Such a shame to watch the leaders of this company continue to make mistake after mistake. They'd be better off putting the sales force on Welchol again. If it's currently generating $700 million annually with very little promotion, just think what it could do if the field had more skin in the game and actually sold Welchol? 20% product weighting, with a limited call plan is a huge miss. Change it to 50% universe and watch Welchol grow to $800 million. That $100 million swing is 5x what they projected Hydexor to do. I know Welchol isn't glorious to sell, but it has no competition, there's no R&D to pay for, we have excellent MC coverage and doctors are familiar with it.

    Let's get back to generating revenue instead of overpaying for niche drugs that ultimately lose money for the company.